WALTHAM, Mass., Sept. 14, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will participate in the Stifel 2023 Immunology & Inflammation Virtual Summit.
Read more at prnewswire.comAeglea BioTherapeutics to Participate in Upcoming September Conference
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here